CompletedHealthcare22 October 2026

Janel Corporation to acquire EnCor Biotechnology Inc.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Janel Corporation
Target
EnCor Biotechnology Inc.
Deal value
USD 17,000,000
Announced
22 October 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
cash, loan-note
What we know

Janel Corporation, through its wholly owned subsidiary Antibodies Incorporated, completed the acquisition of EnCor Biotechnology Inc. on October 20, 2026. Under the Purchase Agreement, Antibodies Inc. acquired 100% of the issued and outstanding shares of common stock of EnCor, a Gainesville, Florida-based company that develops, manufactures, and distributes antibodies and reagents used in the research and treatment of neurological diseases and conditions.

Consideration consisted of $11,960,000 in closing cash plus a subordinated promissory note dated October 20, 2026 with a principal amount of $5,040,000, together totaling $17,000,000. Janel funded the acquisition with cash from operations, borrowings under its Senior Credit Facility, and issuance of the subordinated note.

In connection with the transaction, Janel and its lender group, led by Santander Bank, N.A. as administrative agent, entered into a Waiver, Consent, Joinder, and Second Amendment to Credit Agreement on October 16, 2026. The amendment increased acquisition facility commitments by $15,000,000, of which $11,000,000 was immediately funded by the lenders and used as cash consideration for the EnCor acquisition on October 20, 2026. The amendment also added an excess cash flow mandatory prepayment provision and included lender waivers and consent for provisions that would otherwise have restricted the acquisition.

EnCor was joined as a borrower under the Senior Credit Facility contemporaneously with the closing of the acquisition. Janel disclosed the transaction in a Form 8-K filed on October 22, 2026, with the underlying Purchase Agreement filed as an exhibit to that report.

The archive tags include a loan note. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.

Deal timeline

1 update
  1. CompletedClosed

    Janel Corporation completes acquisition of EnCor Biotechnology Inc.

    Item 1.01 Entry into a Material Definitive Agreement Purchase Agreement On October 20, 2026, Janel Corporation, a Nevada corporation (the “Company”), through its wholly owned subsidiary Antibodies Incorporated, a California corporation (“Antibodies Inc.”), entered into a Purchase Agreement (the “Purchase Agreement”) with EnCor Biotechnology Inc., a Florida Corporation (“EnCor”), whereby Antibodies

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Janel Corporation

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive